Novel Chemotherapy Agent Appears to be a Promising Pancreatic Cancer Treatment
June 20, 2012
- BAY 86-9766 offers survival benefit in mouse model of pancreatic cancer.
- Treatment yields remarkable tumor regression rapidly.
- Therapy effective in mice with advanced tumors.
LAKE TAHOE, Nev. — A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising future treatment for pancreatic ductal adenocarcinoma (PDAC), according to preclinical results presented at the American Association for Cancer Research’s Pancreatic Cancer: Progress and Challenges
conference, held here June 18-21.
“We showed in our endogenous mouse model that our novel chemotherapeutic agent leads to dramatic tumor shrinkage after only one week of treatment,” said Nicole Teichmann, Ph.D., of the Klinikum rechts der Isar at the Technische Universität München in Munich, Germany. “Moreover, the therapy was as effective in animals with advanced tumors and ascites, which is often the case if patients come to the clinic.”
In this preclinical therapeutic study, BAY 86-9766 was evaluated in one of the most aggressive mouse models for PDAC, according to Teichmann. The researchers induced endogenous genetic alterations in these mice, and within eight weeks, the mice developed invasive, lethal PDAC. These genetic alterations closely mimic what is found in most human cases of the disease, she said.
“The mutations trigger the onset of a signaling cascade that is necessary for the survival and proliferation of the cancer cells,” Teichmann said. “Our novel chemotherapeutic drug inhibits one essential protein of this cascade and therefore leads to the cascade’s shutdown.”
A daily treatment of 25 mg/kg with BAY 86-9766 prolonged the survival of the mice in the study compared to their ‘placebo’-treated counterparts; median survival advantage was 20 days. The treatment caused dramatic tumor regression after only one week and was effective in animals with advanced tumors and ascites, which is often how patients present to the clinic.
“We were really surprised that the tumor load dramatically decreases after one week of therapy and also that the treatment conferred such a strong overall survival benefit,” Teichmann said. “Previous studies with gemcitabine, the standard-of-care agent for PDAC since 1997, or other novel inhibitors tested in our lab with the same mouse model showed no or only very modest effects. In our hands, this is the first targeted drug to have shown such strong tumor effects in an endogenous mouse model of PDAC.”
In most animals, the tumor relapsed after three weeks of treatment, which modeled the situation in humans. “Often patients respond to a therapy and after a while, the tumor relapses,” she added. “We can exploit this same tumor relapse in the mouse to investigate the resistance mechanism to improve the therapeutic strategy.”
These findings encourage testing in mouse models rather than xenograft models. “Our results support testing novel agents for pancreatic cancer in endogenous mouse models, rather than conventional xenograft models because they take into account the genetic and morphological heterogeneity of the disease and may be more predictive with regard to efficacy,” Teichmann said.
# # #
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.orgAbout the AACR
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR’s membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org
(215) 446-7109Jeremy.Moore@aacr.org In Lake Tahoe, June 18-20: